ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis

ClinicalTrials.gov ID: NCT01222260

Public ClinicalTrials.gov record NCT01222260. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 8:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase II Study of the Combination of Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis

Study identification

NCT ID
NCT01222260
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Columbia University
Other
Enrollment
40 participants

Conditions and interventions

Conditions

Interventions

  • Bendamustine Drug
  • Dexamethasone Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2012
Primary completion
Feb 28, 2019
Completion
Jul 2, 2019
Last update posted
Mar 29, 2020

2013 – 2019

United States locations

U.S. sites
6
U.S. states
3
U.S. cities
3
Facility City State ZIP Site status
Tufts Medical Center Boston Massachusetts 02111
Boston Medical Center Boston Massachusetts 02118
Barbara Ann Karmanos Cancer Institute Detroit Michigan 48201
Mt. Sinai Medical Center New York New York 10023
Columbia University New York New York 10032
Memorial Sloan-Kettering Cancer Center New York New York 10065

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01222260, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 29, 2020 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01222260 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →